Press releases

May 13, 2021
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
March 5, 2021
Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 4, 2021
Compass Therapeutics Announces Participation in March 2021 Investor Conferences
March 4, 2021
Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol “CMPX”
January 19, 2021
Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference
September 15, 2020
Compass Therapeutics, Inc. Provides Corporate Update
August 24, 2020
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models
June 23, 2020
Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement
March 30, 2020
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137
February 28, 2020
Compass Therapeutics to Present at the 40th Cowen Health Care Conference
January 6, 2020
Compass Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
December 2, 2019
Compass Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
October 24, 2019
Compass Therapeutics to Present Preclinical Data on a Novel PD-1/PD-L1 Bispecific Antibody and from its Proprietary Innate Cell Engager Platform at the 2019 SITC Meeting
October 22, 2019
Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory Board
August 1, 2019
Compass Therapeutics Appoints Julie Sunderland to Board of Directors
July 8, 2019
Compass Therapeutics Announces First Patient Dosed in Phase 1 Trial of CTX-471
June 17, 2019
Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471
March 24, 2019
Compass at Keystone’s Cancer Immunotherapy Symposium (March 24-28) in Keystone, Colorado
March 12, 2019
Compass at the Cowen & Co. 39th Annual Health Care Conference 2019
January 3, 2019
Compass Therapeutics to Present at J.P. Morgan Healthcare Conference
November 26, 2018
Compass Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 6, 2018
Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
October 2, 2018
FierceBiotech Names Compass Therapeutics a 2018 “Fierce 15” Biotech Company
July 12, 2018
Compass Therapeutics Completes $132 Million Series A Financing To Advance Next-Generation Antibody-Based Therapeutics Into The Clinic